Stayble Therapeutics AB (STABL) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.194x

Based on the latest financial reports, Stayble Therapeutics AB (STABL) has a cash flow conversion efficiency ratio of -0.194x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.34 Million ≈ $-144.31K USD) by net assets (Skr6.92 Million ≈ $744.92K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Stayble Therapeutics AB for the company's overall valuation and market capitalisation.

Stayble Therapeutics AB - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Stayble Therapeutics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Stayble Therapeutics AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Stayble Therapeutics AB ranked by their cash flow conversion efficiency. See STABL operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Moab Minerals Ltd AU:MOM	-0.120x
Rainbow Polikarbonat Sanayi Ticaret AS IS:RNPOL	0.103x
Ausmon Resources Ltd AU:AOA	-0.232x
Sky Gold Corp V:SKYG	-0.256x
FDM Group Holdings PLC LSE:FDM	0.193x
Bohra Industries Limited NSE:BOHRAIND	0.009x
Nexoptic Technology Corp V:NXO	-0.011x
Moovly Media Inc V:MVY	0.016x

Annual Cash Flow Conversion Efficiency for Stayble Therapeutics AB (2016–2025)

The table below shows the annual cash flow conversion efficiency of Stayble Therapeutics AB from 2016 to 2025. View Stayble Therapeutics AB stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr6.92 Million ≈ $744.92K	Skr-6.72 Million ≈ $-723.29K	-0.971x	+54.50%
2024-12-31	Skr6.87 Million ≈ $739.64K	Skr-14.67 Million ≈ $-1.58 Million	-2.134x	-49.66%
2023-12-31	Skr16.51 Million ≈ $1.78 Million	Skr-23.54 Million ≈ $-2.53 Million	-1.426x	+12.45%
2022-12-31	Skr15.28 Million ≈ $1.64 Million	Skr-24.89 Million ≈ $-2.68 Million	-1.628x	-572.99%
2021-12-31	Skr39.81 Million ≈ $4.28 Million	Skr-9.63 Million ≈ $-1.04 Million	-0.242x	+84.31%
2020-12-31	Skr15.55 Million ≈ $1.67 Million	Skr-23.98 Million ≈ $-2.58 Million	-1.542x	-57.46%
2019-12-31	Skr-295.44K ≈ $-31.79K	Skr289.39K ≈ $31.14K	-0.980x	-28.49%
2018-12-31	Skr7.11 Million ≈ $765.43K	Skr-5.42 Million ≈ $-583.53K	-0.762x	-140.22%
2017-12-31	Skr8.25 Million ≈ $887.43K	Skr-2.62 Million ≈ $-281.63K	-0.317x	-152.05%
2016-12-31	Skr11.06 Million ≈ $1.19 Million	Skr-1.39 Million ≈ $-149.87K	-0.126x	--

About Stayble Therapeutics AB

ST:STABL Sweden Biotechnology

Market Cap

$1.42 Million

Skr13.19 Million SEK

Market Cap Rank

#30434 Global

#699 in Sweden

Share Price

Skr0.21

Change (1 day)

+0.00%

52-Week Range

Skr0.03 - Skr0.35

All Time High

Skr16.95